Hospital Universitari Arnau De Vilanova De La Gerencia Territorial De Lleida
Verified
Lleida, Spain
Rare diseases
Investigational molecules
Locations
A plain-language summary of the goals, design and what participants do
This study involves patients who have suffered a head injury and require care in an intensive care unit. The injury being studied is specifically moderate or severe traumatic brain injury, which is a serious condition that occurs when an external force causes damage to the brain. The study will compare two treatments: propranolol hydrochloride, which is a medication that belongs to a group of medicines called beta-blockers that affect the heart and blood circulation, and placebo. Some patients will also receive methylcellulose as part of the study. Both treatments will be given by mouth in tablet or capsule form for a period of 14 days.
The purpose of the study is to compare survival rates in the hospital between patients who receive propranolol and those who receive placebo. The study will look at whether propranolol can help reduce the number of deaths that occur in the hospital among patients with traumatic brain injury who are admitted to the intensive care unit. The study will also examine the overall recovery and functional outcome of patients using a measurement scale that assesses how well patients are able to function after their injury.
Patients can be enrolled in the study within the first 96 hours after their injury occurs. Before treatment begins, patients must be in stable condition with adequate blood pressure, heart rate, and blood flow to the brain. The treatment will continue for 14 days with a maximum daily dose of 240 milligrams. Patients or their legal representatives must provide consent to participate in the study. The study is designed so that neither the patients, their doctors, nor the researchers know which treatment is being given during the study period.
The trial runs in 4 steps – from screening to follow-up. Each step says what happens and what the team monitors.
7 criteria
1 criterion
Tell us about your condition – we search every trial in Europe and connect you with the right site.
We usually reply within a few days
All sites with verified contact details – recruitment status may not be available; ask directly
Lleida, Spain
Madrid, Spain
Badalona, Spain
Where you can join this trial
Countries are shaded by recruitment status. Click a recruiting country to ask about joining there.
Not yet recruitingJoining a clinical trial can seem overwhelming. We guide you step by step, so you know exactly what to expect and how we support you through the process.
Propranolol is a medication that belongs to a group of medicines called beta-blockers. It works by slowing down the heart rate and reducing the force of heart contractions. In this trial, propranolol is being tested to see if it can help reduce death rates in patients with traumatic brain injury who need intensive care treatment.
sourced from the EU Clinical Trials Register and site verification
Want to learn more about this trial or check if you can participate?
Tell us about your condition – we search every trial in Europe and connect you with the right site.